Liraglutide meets stricter FDA rules, Novo Nordisk says

03/25/2009 | Bloomberg

Clinical data show liraglutide does not increase heart risks and might even reduce them, leading Novo Nordisk officials to think the firm's diabetes drug will overcome regulatory hurdles that have plagued rival treatments, including Takeda's alogliptin. An FDA panel is set April 2 to evaluate whether liraglutide complies with the agency's new safety guidelines on the cardiovascular effects of diabetes medicines.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC